Phenotypes Associated with This Genotype

Genotype
MGI:7657886

• Allelic Composition: Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi}; Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺
• Genetic Background: B6.Cg-Ctps1^{tm1c(KOMP)Wtsi} Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

weight loss ( J:348981 )

• mice show a drastic weight loss upon tamoxifen treatment by day 6

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:348981 )

• tamoxifen-treated mice show numerous empty crypts and vacuoles

small thymus ( J:348981 )

• thymus is smaller in tamoxifen-treated mice

thymus hypoplasia ( J:348981 )

• thymus cellularity is reduced 10-fold in tamoxifen-treated mice

abnormal thymus physiology ( J:348981 )

• most cells in the thymus of tamoxifen-treated mice are CD4-/CD8- double negative, suggesting impaired proliferation capacity of early thymocytes

digestive/alimentary system

abnormal intestinal epithelium morphology ( J:348981 )

• tamoxifen-treated mice exhibit aberrant gut structures, with lamina propria that is detaching from the epithelium and abnormal cell shedding at the top of the villi

abnormal small intestine crypts of Lieberkuhn morphology ( J:348981 )

• tamoxifen-treated mice show numerous empty crypts and vacuoles

abnormal small intestinal villus morphology ( J:348981 )

• abnormal cell shedding at the top of the villi in tamoxifen-treated mice

decreased small intestinal villus height ( J:348981 )

• length of villi is reduced in tamoxifen-treated mice

hematopoietic system

decreased T cell proliferation ( J:348981 )

• the expansion of splenic T cells in response to CD3 and CD28 stimulation is impaired in tamoxifen-treated mice

• proliferation of sorted splenic B cells upon stimulation with LPS plus IL-4 is reduced in tamoxifen-treated mice

small thymus ( J:348981 )

• thymus is smaller in tamoxifen-treated mice

thymus hypoplasia ( J:348981 )

• thymus cellularity is reduced 10-fold in tamoxifen-treated mice

abnormal thymus physiology ( J:348981 )

• most cells in the thymus of tamoxifen-treated mice are CD4-/CD8- double negative, suggesting impaired proliferation capacity of early thymocytes

decreased erythrocyte cell number ( J:348981 )

• red blood cell numbers are reduced in tamoxifen-treated mice

decreased hemoglobin content ( J:348981 )

• hemoglobin is reduced in tamoxifen-treated mice

increased CD8-positive, alpha-beta T cell number ( J:348981 )

• spleen shows a slight increase of CD8+ T cells in tamoxifen-treated mice

decreased lymphocyte cell number ( J:348981 )

• lymphocyte numbers are reduced in tamoxifen-treated mice

• however, no differences are seen in total number of whole blood cells and neutrophils

decreased germinal center B cell number ( J:348981 )

• CD19+CD95+GL-7+ germinal center B cells are almost absent in tamoxifen-treated mice (activated B cells)

• however, proportions of T and B cells in Peyers patches are normal

decreased T follicular helper cell number ( J:348981 )

• CXCR5+PD-1+ T follicular helper cells are reduced in germinal centers of tamoxifen-treated mice

• percentage of CXCR5+PD-1+ T follicular helper cells is reduced after immunization with NP-CGG

reticulocytopenia ( J:348981 )

• tamoxifen-treated mice show a drop in reticulocyte numbers

abnormal spleen morphology ( J:348981 )

• spleen shows a cellularity and composition similar to controls except for a slight increase of CD8+ T cells

decreased IgM level ( J:348981 )

• tamoxifen-treated mice immunized with NP-CGG show a reduction of NP-specific IgM

immune system

decreased T cell proliferation ( J:348981 )

• the expansion of splenic T cells in response to CD3 and CD28 stimulation is impaired in tamoxifen-treated mice

• proliferation of sorted splenic B cells upon stimulation with LPS plus IL-4 is reduced in tamoxifen-treated mice

small thymus ( J:348981 )

• thymus is smaller in tamoxifen-treated mice

thymus hypoplasia ( J:348981 )

• thymus cellularity is reduced 10-fold in tamoxifen-treated mice

abnormal thymus physiology ( J:348981 )

• most cells in the thymus of tamoxifen-treated mice are CD4-/CD8- double negative, suggesting impaired proliferation capacity of early thymocytes

increased CD8-positive, alpha-beta T cell number ( J:348981 )

• spleen shows a slight increase of CD8+ T cells in tamoxifen-treated mice

decreased lymphocyte cell number ( J:348981 )

• lymphocyte numbers are reduced in tamoxifen-treated mice

• however, no differences are seen in total number of whole blood cells and neutrophils

decreased germinal center B cell number ( J:348981 )

• CD19+CD95+GL-7+ germinal center B cells are almost absent in tamoxifen-treated mice (activated B cells)

• however, proportions of T and B cells in Peyers patches are normal

decreased T follicular helper cell number ( J:348981 )

• CXCR5+PD-1+ T follicular helper cells are reduced in germinal centers of tamoxifen-treated mice

• percentage of CXCR5+PD-1+ T follicular helper cells is reduced after immunization with NP-CGG

abnormal spleen morphology ( J:348981 )

• spleen shows a cellularity and composition similar to controls except for a slight increase of CD8+ T cells

decreased IgM level ( J:348981 )

• tamoxifen-treated mice immunized with NP-CGG show a reduction of NP-specific IgM

impaired humoral immune response ( J:348981 )

• capacity to mount humoral immune responses against the T-dependent antigen 4-hydroxy-3-nitrophenyl (NP) hapten conjugated to chicken gamma globulin (CGG) is reduced in tamoxifen-treated mice

• spleen histology after immunization with NP-CGG shows a reduction of proliferating B cells

cellular

decreased T cell proliferation ( J:348981 )

• the expansion of splenic T cells in response to CD3 and CD28 stimulation is impaired in tamoxifen-treated mice

• proliferation of sorted splenic B cells upon stimulation with LPS plus IL-4 is reduced in tamoxifen-treated mice